UNSPSC 51113202: Benzodepa

This classification denotes an ethylenimine compound with the molecular formula C12H16N3O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q30T24YM3F, chemically known as carbamic acid, (bis(1-aziridinyl)phosphinyl)-, phenylmethyl ester but more generally known as benzodepa, which bears US NIH Compound Identifier 16111. European Medicines Agency schedules Benzodepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05758MIG.

UNSPSC 51113202 Benzodepa, a Commodity code, designates a nitrogen mustard alkylating agent used in oncology and hematology treatment protocols. State and local procurement activity under this code reflects purchases of this pharmaceutical preparation by public health systems, corrections departments, and regional medical centers for cancer therapy and blood disorder management. The code encompasses the drug itself as a finished pharmaceutical product, typically acquired through competitive solicitation against established state or regional formulary contracts, GPO agreements, or direct procurement vehicles. Issuing bodies include state departments of health, county hospital systems, municipal healthcare facilities, and state prison medical services, though activity under this specific code remains modest relative to broader pharmaceutical procurement across state and local government.

The source provides no recent state or local contract opportunities specifically tagged to UNSPSC 51113202, and no geographic concentration or representative recent solicitations can be identified. This reflects the narrow and specialized nature of the pharmaceutical — benzodepa is a less commonly used agent compared to other oncology chemotherapy drugs, and procurement tends to flow through standing pharmacy contracts or group purchasing organizations rather than through visible individual-line-item solicitations. Activity under this code, when it occurs, typically appears embedded within larger RFPs or ITBs for pharmaceutical supply agreements rather than as a standalone procurement notice.